Skip to main content

Drug Interactions between nifurtimox and Vowst

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

nifurtimox fecal microbiota spores, live

Applies to: nifurtimox and Vowst (fecal microbiota spores, live)

GENERALLY AVOID: Antibiotics may interfere with the therapeutic effects of oral fecal microbiota, which contains live bacterial spores. The mechanism may be related to the antibiotic inactivating the bacterial spores or reducing bacterial replication. However, the clinical significance of this interaction has not been established.

MANAGEMENT: Concomitant use of oral fecal microbiota spores with antibiotics should generally be avoided. The manufacturer of the oral formulation of fecal microbiota recommends that treatment commence two to four days after completing antibiotic treatment for Clostridium difficile infection.

References (1)
  1. (2023) "Product Information. Vowst (fecal microbiota spores, live)." Aimmune Therapeutics

Drug and food interactions

Major

nifurtimox food

Applies to: nifurtimox

CONTRAINDICATED: Use of alcohol or products containing alcohol during therapy with nitrofurans may result in a disulfiram-like reaction in some patients. The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by nitrofurans in a manner similar to disulfiram. Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the 'disulfiram reaction'. Symptoms include flushing, throbbing in head and neck, throbbing headache, respiratory difficulty, nausea, vomiting, sweating, thirst, chest pain, palpitation, dyspnea, hyperventilation, tachycardia, hypotension, syncope, weakness, vertigo, blurred vision, and confusion. Severe reactions may result in respiratory depression, cardiovascular collapse, arrhythmia, myocardial infarction, acute congestive heart failure, unconsciousness, convulsions, and death.

ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of nifurtimox. When a single 120 mg oral dose of nifurtimox was administered with a high-fat meal (800 to 1000 calories; approximately 60% fat) in adult Chagas patients, nifurtimox peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 68% and 71%, respectively, compared to administration under fasted conditions. Nifurtimox was administered with food in clinical trials.

MANAGEMENT: Consumption of alcohol is considered contraindicated during nifurtimox therapy. To ensure maximal oral absorption, nifurtimox should be administered with food.

References (1)
  1. (2020) "Product Information. Lampit (nifurtimox)." Bayer Pharmaceutical Inc
Moderate

fecal microbiota spores, live food

Applies to: Vowst (fecal microbiota spores, live)

ADJUST DOSING INTERVAL: There are no data regarding the effects of concurrent administration of oral fecal microbiota spores with food.

MANAGEMENT: The manufacturer of the oral formulation of fecal microbiota recommends that patients should have no food or drink except for a small amount of water for at least 8 hours prior to the first dose of fecal microbiota spores. The second and third doses of fecal microbiota spores should be taken on an empty stomach prior to the first meal of the day.

References (1)
  1. (2023) "Product Information. Vowst (fecal microbiota spores, live)." Aimmune Therapeutics

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.